HK1071308A1 - Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist - Google Patents

Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Info

Publication number
HK1071308A1
HK1071308A1 HK05104255A HK05104255A HK1071308A1 HK 1071308 A1 HK1071308 A1 HK 1071308A1 HK 05104255 A HK05104255 A HK 05104255A HK 05104255 A HK05104255 A HK 05104255A HK 1071308 A1 HK1071308 A1 HK 1071308A1
Authority
HK
Hong Kong
Prior art keywords
pde3
pde4
inhibitor
pharmaceutical composition
receptor antagonist
Prior art date
Application number
HK05104255A
Other languages
English (en)
Inventor
Beume Rolf
Bundshuh Daniela
Weimar Christian
Wollin Stefan-Lutz
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of HK1071308A1 publication Critical patent/HK1071308A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK05104255A 2002-03-06 2005-05-20 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist HK1071308A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06
PCT/EP2003/001876 WO2003074055A1 (en) 2002-03-06 2003-02-25 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Publications (1)

Publication Number Publication Date
HK1071308A1 true HK1071308A1 (en) 2005-07-15

Family

ID=27771841

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104255A HK1071308A1 (en) 2002-03-06 2005-05-20 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Country Status (32)

Country Link
US (1) US20050112069A1 (pt)
EP (2) EP1849468B1 (pt)
JP (1) JP5150034B2 (pt)
KR (1) KR20040095255A (pt)
CN (1) CN101257904A (pt)
AR (1) AR038858A1 (pt)
AT (1) ATE369134T1 (pt)
AU (1) AU2003212268B2 (pt)
BR (1) BR0308220A (pt)
CA (1) CA2478612C (pt)
CO (1) CO5611148A2 (pt)
CY (2) CY1106927T1 (pt)
DE (1) DE60315426T2 (pt)
DK (2) DK1849468T3 (pt)
EA (2) EA010886B1 (pt)
ES (2) ES2291618T3 (pt)
HK (1) HK1071308A1 (pt)
HR (1) HRP20040909B1 (pt)
IL (1) IL163336A (pt)
IS (2) IS2536B (pt)
MX (1) MXPA04008460A (pt)
NO (1) NO335254B1 (pt)
NZ (1) NZ535611A (pt)
PL (1) PL211574B1 (pt)
PT (2) PT1482938E (pt)
RS (1) RS51018B (pt)
SG (1) SG160197A1 (pt)
SI (2) SI1482938T1 (pt)
TW (1) TWI347845B (pt)
UA (1) UA80117C2 (pt)
WO (1) WO2003074055A1 (pt)
ZA (1) ZA200407104B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618643A2 (pt) * 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
ES2341813T3 (es) * 2006-12-20 2010-06-28 Glaxo Group Limited 4-bencil-1 (2h)-ftalazinonas como antagonistas del receptor h1.
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2008127975A2 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US8877816B2 (en) 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 p-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
WO2012107363A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
CA2993462A1 (en) * 2014-08-26 2016-03-03 Fundacion Para La Investigacion Medica Aplicada Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases
MX2017004655A (es) * 2014-10-09 2018-03-27 Guangdong Zhongsheng Pharmaceutical Co Ltd Compuestos de hidroxil purinas y aplicaciones de estos.
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5712298A (en) * 1993-07-02 1998-01-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
MXPA02003581A (es) * 1999-10-25 2002-10-23 Altana Pharma Ag Derivados de ranftalazinona de tetrahidrotiopia como inhibidores pde4.
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
ZA200407104B (en) 2006-12-27
NZ535611A (en) 2006-03-31
RS51018B (sr) 2010-10-31
AU2003212268B2 (en) 2008-09-11
IS8760A (is) 2008-09-04
UA80117C2 (uk) 2007-08-27
NO335254B1 (no) 2014-10-27
EA010886B1 (ru) 2008-12-30
HRP20040909B1 (en) 2012-11-30
CO5611148A2 (es) 2006-02-28
JP2005524666A (ja) 2005-08-18
TWI347845B (en) 2011-09-01
DK1482938T3 (da) 2007-12-03
CA2478612C (en) 2013-12-10
MXPA04008460A (es) 2004-12-06
SI1849468T1 (sl) 2013-03-29
CY1106927T1 (el) 2012-09-26
EA200601592A1 (ru) 2006-12-29
EP1482938B1 (en) 2007-08-08
PL371056A1 (en) 2005-06-13
CN101257904A (zh) 2008-09-03
IL163336A (en) 2009-02-11
HRP20040909A2 (en) 2005-08-31
CY1113894T1 (el) 2016-07-27
EP1849468A3 (en) 2007-11-07
TW200306855A (en) 2003-12-01
ES2291618T3 (es) 2008-03-01
ES2400670T3 (es) 2013-04-11
RS78004A (en) 2006-12-15
DE60315426D1 (de) 2007-09-20
IS7438A (is) 2004-09-03
KR20040095255A (ko) 2004-11-12
ATE369134T1 (de) 2007-08-15
CA2478612A1 (en) 2003-09-12
BR0308220A (pt) 2005-01-04
IS2536B (is) 2009-08-15
WO2003074055A1 (en) 2003-09-12
PT1482938E (pt) 2007-11-15
SG160197A1 (en) 2010-04-29
EA200401137A1 (ru) 2005-04-28
AU2003212268A1 (en) 2003-09-16
NO20044230L (no) 2004-12-06
EA007903B1 (ru) 2007-02-27
EP1849468B1 (en) 2012-12-05
US20050112069A1 (en) 2005-05-26
DE60315426T2 (de) 2008-07-03
DK1849468T3 (da) 2013-02-04
AR038858A1 (es) 2005-01-26
JP5150034B2 (ja) 2013-02-20
SI1482938T1 (sl) 2007-12-31
EP1849468A2 (en) 2007-10-31
EP1482938A1 (en) 2004-12-08
PT1849468E (pt) 2013-02-27
PL211574B1 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
HK1071308A1 (en) Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
IL159588A0 (en) Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
HUP0302615A3 (en) Kinase inhibitor quinazoline derivatives and pharmaceutical compositions containing them and their use
AU2003252478A1 (en) Ccr4 antagonist and medicinal use thereof
PL374878A1 (en) Use of cetp inhibitors and optionally hmg coa reductable inhibitors and/or antihypertensive agents
PL375977A1 (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
AU2002231570A1 (en) Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant
IL153645A0 (en) Carboxamide compounds and their use as antagonists of a human 11cby receptor
IL205407A0 (en) Hyaluronic acid antagonist and inhibitor compositions and uses thereof
IL159538A0 (en) 8/17 heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors
AP2003002719A0 (en) Use of cox-2 inhibitors for preventing immunodeficiency
HUP0400654A3 (en) Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
IL159040A0 (en) A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function
AU2002227123A1 (en) Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
HUP0500078A3 (en) Pharmaceutical composition containing a combination of a pde inhibitor and a leukotriene receptor antagonist
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
AU2003206014A8 (en) Neuropeptide receptor and uses thereof
IL148292A0 (en) Pharmaceutical compositions of halofuginone and other quinazolinone derivatives
AU2003231019A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING Alpha3Beta4 NICOTINIC RECEPTOR ANTAGONISTS AND METHODS OF THEIR USE
HUP0301728A3 (en) Hmg-coa reductase inhibiting pharmaceutical compositions and their use
HK1077230A1 (en) Medicinal composition hmg-coa reductase inhibitor
AU2002339817A1 (en) Use of inhibitors of the y2 receptor of neuropeptide y in the treatment of alcoholism
AU2002354760A1 (en) Glucocorticoid-induced receptor and methods of use
AU2002322290A1 (en) Vitamin d receptor antagonists and related compositions and methods of use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160225